Need Help?

Combining dasatinib and IFN-α in CML – immunomodulatory effects linked to treatment response and adverse events

We pooled 100,000 cells from the 12 scRNA+TCRab-seq samples from peripheral blood from three time points (n=4, samples at 0, 3, and 12 months) to understand the landscape of immune subsets in CML during the course of dasatinib+IFN-α treatment

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001009085 Illumina HiSeq 2500 48
EGAD00001009086 Illumina NovaSeq 6000 48
Publications Citations
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
J Clin Invest 132: 2022 e152585
3